OraSure Technologies Inc. (NASDAQ:OSUR) CEO Douglas A. Michels sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, September 26th. The shares were sold at an average price of $8.22, for a total value of $205,500.00. Following the completion of the transaction, the chief executive officer now directly owns 756,898 shares in the company, valued at approximately $6,221,701.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of OraSure Technologies Inc. (NASDAQ:OSUR) opened at 7.89 on Friday. The company has a 50-day moving average price of $8.06 and a 200 day moving average price of $7.24. OraSure Technologies Inc. has a 52-week low of $4.40 and a 52-week high of $9.05. The firm has a market capitalization of $438.68 million, a PE ratio of 37.57 and a beta of 1.25.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.02. The company had revenue of $31.36 million for the quarter, compared to the consensus estimate of $31.15 million. OraSure Technologies had a return on equity of 7.60% and a net margin of 10.08%. The company’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.03 earnings per share. Analysts expect that OraSure Technologies Inc. will post $0.27 EPS for the current fiscal year.
A number of research analysts recently weighed in on the company. Raymond James Financial Inc. lowered OraSure Technologies from an “outperform” rating to a “market perform” rating and set a $8.00 price objective on the stock. in a report on Monday, June 13th. Canaccord Genuity boosted their target price on OraSure Technologies from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, August 24th. Jefferies Group reduced their price objective on OraSure Technologies from $8.50 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, August 4th. BTIG Research restated a “buy” rating on shares of OraSure Technologies in a research report on Wednesday, August 24th. Finally, Mizuho restated an “outperform” rating and issued a $8.00 price objective on shares of OraSure Technologies in a research report on Tuesday, July 5th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. OraSure Technologies currently has a consensus rating of “Buy” and a consensus target price of $8.58.
Several hedge funds and other institutional investors have recently made changes to their positions in OSUR. TIAA CREF Investment Management LLC increased its position in shares of OraSure Technologies by 3.2% in the first quarter. TIAA CREF Investment Management LLC now owns 586,982 shares of the company’s stock valued at $4,244,000 after buying an additional 18,442 shares during the last quarter. Mckinley Capital Management LLC Delaware acquired a new position in shares of OraSure Technologies during the first quarter valued at approximately $2,094,000. State Street Corp increased its position in shares of OraSure Technologies by 3.5% in the first quarter. State Street Corp now owns 1,036,316 shares of the company’s stock valued at $7,490,000 after buying an additional 35,038 shares during the last quarter. Algert Global LLC acquired a new position in shares of OraSure Technologies during the first quarter valued at approximately $187,000. Finally, Strs Ohio increased its position in shares of OraSure Technologies by 205.7% in the second quarter. Strs Ohio now owns 97,200 shares of the company’s stock valued at $574,000 after buying an additional 65,400 shares during the last quarter. 79.65% of the stock is currently owned by institutional investors and hedge funds.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.